279 related articles for article (PubMed ID: 34884669)
21. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
22. Results Obtained from a Pivotal Validation Trial of a Microsatellite Analysis (MSA) Assay for Bladder Cancer Detection through a Statistical Approach Using a Four-Stage Pipeline of Modern Machine Learning Techniques.
Reynolds T; Riddick G; Meyers G; Gordon M; Flores Monar GV; Moon D; Moon C
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203643
[TBL] [Abstract][Full Text] [Related]
23. An updated review of microsatellite instability in the era of next-generation sequencing and precision medicine.
Yamamoto H; Imai K
Semin Oncol; 2019 Jun; 46(3):261-270. PubMed ID: 31537299
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.
Lekili M; Sener E; Demir MA; Temeltaş G; Müezzinoğlu T; Büyüksu C
Urol Res; 2004 May; 32(2):124-8. PubMed ID: 14685796
[TBL] [Abstract][Full Text] [Related]
25. Microsatellite instability as prognostic marker in bladder tumors: a clinical significance.
Vaish M; Mandhani A; Mittal RD; Mittal B
BMC Urol; 2005 Jan; 5():2. PubMed ID: 15647110
[TBL] [Abstract][Full Text] [Related]
26. Current Use and Promise of Urinary Markers for Urothelial Cancer.
Tabayoyong W; Kamat AM
Curr Urol Rep; 2018 Oct; 19(12):96. PubMed ID: 30328534
[TBL] [Abstract][Full Text] [Related]
27. Recent advances in bladder cancer diagnostics.
Sanchez-Carbayo M
Clin Biochem; 2004 Jul; 37(7):562-71. PubMed ID: 15234237
[TBL] [Abstract][Full Text] [Related]
28. Patients with a negative cystoscopy and negative Nmp22® Bladderchek® test are at low risk of missed transitional cell carcinoma of the bladder: a prospective evaluation.
Terrell JD; Elias KJ; Sagalowsky AI; Lotan Y
Int Braz J Urol; 2011; 37(6):706-11. PubMed ID: 22234001
[TBL] [Abstract][Full Text] [Related]
29. Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer.
Fantony JJ; Abern MR; Gopalakrishna A; Owusu R; Jack Tay K; Lance RS; Inman BA
Urol Oncol; 2015 Sep; 33(9):387.e1-6. PubMed ID: 26027762
[TBL] [Abstract][Full Text] [Related]
30. Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection.
Wallace E; Higuchi R; Satya M; McCann L; Sin MLY; Bridge JA; Wei H; Zhang J; Wong E; Hiar A; Mach KE; Scherr D; Egerdie RB; Ohta S; Sexton WJ; Meng MV; Weizer AZ; Woods M; Jansz GK; Zadra J; Lotan Y; Goldfarb B; Liao JC
J Urol; 2018 Mar; 199(3):655-662. PubMed ID: 29061538
[TBL] [Abstract][Full Text] [Related]
31. [Urinary cytology in cases of bladder cancer: a critical evaluation].
Rathert P
Urologe A; 2003 Jul; 42(7):908-11. PubMed ID: 12898033
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence.
Eissa S; Zohny SF; Zekri AR; El-Zayat TM; Maher AM
Med Oncol; 2010 Dec; 27(4):1286-94. PubMed ID: 20012564
[TBL] [Abstract][Full Text] [Related]
33. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
34. Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine.
Golijanin D; Sherman Y; Shapiro A; Pode D
Urology; 1995 Aug; 46(2):173-7. PubMed ID: 7624989
[TBL] [Abstract][Full Text] [Related]
35. Performance characteristics of multiple urinary tumor markers and sample collection techniques in the detection of transitional cell carcinoma of the bladder.
Bhuiyan J; Akhter J; O'Kane DJ
Clin Chim Acta; 2003 May; 331(1-2):69-77. PubMed ID: 12691866
[TBL] [Abstract][Full Text] [Related]
36. MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
Liu H; He W; Wang B; Xu K; Han J; Zheng J; Ren J; Shao L; Bo S; Lu S; Lin T; Huang J
BMC Cancer; 2018 Jun; 18(1):659. PubMed ID: 29907142
[TBL] [Abstract][Full Text] [Related]
37. Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer.
Abd El Gawad IA; Moussa HS; Nasr MI; El Gemae EH; Masooud AM; Ibrahim IK; El Hifnawy NM
J Egypt Natl Canc Inst; 2005 Sep; 17(3):193-202. PubMed ID: 16799657
[TBL] [Abstract][Full Text] [Related]
38. Urinary level of CA19-9 as a tumor marker in urothelial carcinoma of the bladder.
Pal K; Roy S; Mondal SA; Chatterjee U; Tiwari P; Bera M
Urol J; 2011; 8(3):203-8. PubMed ID: 21910099
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
[TBL] [Abstract][Full Text] [Related]
40. High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array.
Hoque MO; Lee J; Begum S; Yamashita K; Engles JM; Schoenberg M; Westra WH; Sidransky D
Cancer Res; 2003 Sep; 63(18):5723-6. PubMed ID: 14522891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
